Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.

[1]  W. Faigle,et al.  Semen Clusterin Is a Novel DC-SIGN Ligand , 2011, The Journal of Immunology.

[2]  B. Karger,et al.  2D-LC analysis of BRP 3 erythropoietin N-glycosylation using anion exchange fractionation and hydrophilic interaction UPLC reveals long poly-N-acetyl lactosamine extensions. , 2011, Analytical chemistry.

[3]  Mary Ann Comunale,et al.  Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[4]  Pauline M Rudd,et al.  Novel glycan biomarkers for the detection of lung cancer. , 2011, Journal of proteome research.

[5]  Pauline M. Rudd,et al.  Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. , 2011, Journal of proteome research.

[6]  W. Hancock,et al.  Technologies and strategies for glycoproteomics and glycomics and their application to clinical biomarker research. , 2011, Analytical methods : advancing methods and applications.

[7]  P. Rudd,et al.  Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. , 2010, Omics : a journal of integrative biology.

[8]  P. Devarajan.  The promise of biomarkers for personalized renal cancer care. , 2010, Kidney international.

[9]  R. Sutphen,et al.  Urine Collection and Processing for Protein Biomarker Discovery and Quantification , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[10]  Susan J Fisher,et al.  Sweetening the pot: adding glycosylation to the biomarker discovery equation. , 2010, Clinical chemistry.

[11]  Scott R. Kronewitter,et al.  Glycomics and disease markers. , 2009, Current opinion in chemical biology.

[12]  I. Rudan,et al.  Variability, heritability and environmental determinants of human plasma N-glycome. , 2009, Journal of proteome research.

[13]  J. Fitzpatrick,et al.  Biomarkers in renal cell carcinoma , 2009, Current opinion in urology.

[14]  Louise Royle,et al.  Proposal for a standard system for drawing structural diagrams of N‐ and O‐linked carbohydrates and related compounds , 2009, Proteomics.

[15]  Pauline M. Rudd,et al.  Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis , 2009, Disease markers.

[16]  A. Guttman,et al.  Sample preparation for the analysis of complex carbohydrates by multicapillary gel electrophoresis with light-emitting diode induced fluorescence detection. , 2008, Analytical chemistry.

[17]  David J. Harvey,et al.  HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. , 2008, Analytical biochemistry.

[18]  Pauline M. Rudd,et al.  GlycoBase and autoGU: tools for HPLC-based glycan analysis , 2008, Bioinform..

[19]  Louise Royle,et al.  Separation‐based Glycoprofiling Approaches using Fluorescent Labels , 2007, Proteomics.

[20]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[21]  O. Iliopoulos.  Molecular biology of renal cell cancer and the identification of therapeutic targets. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Reichrath,et al.  Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control , 2006, Journal of Molecular Histology.

[23]  W. Kaelin,et al.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. , 2006, The American journal of pathology.

[24]  Pauline M Rudd,et al.  Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. , 2006, Methods in molecular biology.

[25]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[26]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[27]  Yuan-fang Zhang,et al.  Changes inN-acetylglucosaminyltransferase III, IV and V in renal cell carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[28]  F. Pichiorri,et al.  Modulation of different clusterin isoforms in human colon tumorigenesis , 2004, Oncogene.

[29]  M. Ohh,et al.  The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. , 2003, Cancer research.

[30]  B. Aronow,et al.  Essential Requirement of Apolipoprotein J (Clusterin) Signaling for IκB Expression and Regulation of NF-κB Activity* , 2003, Journal of Biological Chemistry.

[31]  I. Trougakos,et al.  Clusterin/apolipoprotein J in human aging and cancer. , 2002, The international journal of biochemistry & cell biology.

[32]  S. Hakomori,et al.  Glycosylation defining cancer malignancy: New wine in an old bottle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Scaltriti,et al.  Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression , 2002, Oncogene.

[34]  H. Miyake,et al.  Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. , 2002, The Journal of urology.

[35]  M. Gorospe,et al.  Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFα cytotoxicity , 2002, Oncogene.

[36]  S. Tsuboi,et al.  Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells , 1999, The EMBO journal.

[37]  G. Pankhurst,et al.  Characterization of the heparin-binding properties of human clusterin. , 1998, Biochemistry.

[38]  C. Furlong,et al.  Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.

[39]  A. Laslop,et al.  Glycoprotein III (Clusterin, Sulfated Glycoprotein 2) in Endocrine, Nervous, and Other Tissues: Immunochemical Characterization, Subcellular Localization, and Regulation of Biosynthesis , 1993, Journal of neurochemistry.

[40]  J. Tschopp,et al.  Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. , 1993, Journal of immunology.

[41]  M. Wilson,et al.  Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. , 1992, Biochimica et biophysica acta.

[42]  M. Peitsch,et al.  Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. , 1991, The Journal of biological chemistry.

[43]  S. Mao,et al.  Purification and characterization of apolipoprotein J. , 1990, The Journal of biological chemistry.